4 insiders reported 9 Form 4 transactions for aTYR PHARMA INC (ATYR) over the past 18 months (most recent 2026-05-28). Recent activity: SCHIMMEL PAUL (Director) Buy 100,000 shares, DENYES NANCY (General Counsel) Buy 2,687 shares, DENYES NANCY (General Counsel) Sell 1,118 shares, Broadfoot Jill Marie (Chief Financial Officer) Buy 3,750 shares, Broadfoot Jill Marie (Chief Financial Officer) Sell 1,558 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-28 | SCHIMMEL PAUL | Director | Buy | 100,000 | $50,000 |
| 2026-02-04 | DENYES NANCY | General Counsel | Buy | 2,687 | $0 |
| 2026-02-04 | DENYES NANCY | General Counsel | Sell | 1,118 | $1,096 |
| 2026-02-04 | Broadfoot Jill Marie | Chief Financial Officer | Buy | 3,750 | $0 |
| 2026-02-04 | Broadfoot Jill Marie | Chief Financial Officer | Sell | 1,558 | $1,527 |
| 2026-02-04 | Shukla Sanjay | President and CEO | Buy | 10,375 | $0 |
| 2026-02-04 | Shukla Sanjay | President and CEO | Sell | 3,745 | $3,670 |
| 2025-10-09 | SCHIMMEL PAUL | Director | Buy | 682,001 | $613,801 |
| 2025-10-09 | SCHIMMEL PAUL | Director | Buy | 317,999 | $298,919 |
来源：SEC Form 4 申报文件 · 截至 2026-05-28